Ionis announces GSK has advanced bepirovirsen into Phase 3 development

CARLSBAD, Calif., Feb. 1, 2023. Ionis Pharmaceuticals, Inc. today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials